For Health Care Professionals Outside the US

In adult patients with relapsed/refractory severe aplastic anaemia (SAA)

REVOLADE Has a
Favourable Safety Profile

REVOLADE was well tolerated and was associated with few limitations to treatment1

Review the SAA study design
  • No dose-limiting toxicities were observed, other than reversible transaminitis
    • This is similar to results seen in much larger efficacy and safety studies in ITP, despite a higher dose of REVOLADE used in SAA2
  • Eight (19%) patients had a new cytogenic abnormality reported while on therapy, including 5 patients who had changes in chromosome 71

References:

1. REVOLADE Core Data Sheet. Version 2.4. 17 June 2019. 2. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818-1825.

© 2019 Novartis | Use of this website is subject to our Terms of Use
Disclaimer: This is an international website for REVOLADE® (eltrombopag) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents links at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.